Baraliakos X, et al. Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. ACR 2018, abstract L13.
Nieuwe antistoffen ontwikkeld die ontsteking remmen bij auto-immuunziekten
dec 2025 | Benigne hematologie, RA